🧬 The Breakthrough Edition #001

How One Woman's Courage Is Transforming the Future of Sickle Cell Disease

Sometimes the biggest breakthroughs in medicine don't begin inside a laboratory.

They begin with one patient willing to say "yes."

Over the past few days, headlines have celebrated a remarkable milestone. Twenty-three-year-old Daniel Cressy of Louisiana has become the first patient in his state to be functionally cured of sickle cell disease through CRISPR gene-editing therapy. For the first time in his life, his blood cells are no longer sickling, giving him the opportunity to pursue his dream of becoming a commercial airline pilot.

It is an extraordinary story.

But the story actually began years before Daniel ever received treatment.

Meet Victoria Gray

In the fall of 2025, I had the privilege of meeting Victoria Gray while attending the DPHARM conference.

For many people, she was the keynote speaker.

For me, she was something even more. 

Two women, two history makers, meeting, hugging and sharing an insight only we could understand.  

Victoria represents the courage behind one of the greatest medical breakthroughs of our generation.  I remember her voice growing with steady excitement as she explained to me the benefits of being the first, living a better quality of life and sharing her story.  

In 2019, Victoria became the first person in the world with sickle cell disease to receive CRISPR gene-editing therapy as part of a clinical trial. At the time, no one knew whether the treatment would work, how long the results would last, or what the future might hold. She wasn't simply receiving a new treatment—she was helping scientists answer one of the biggest questions in modern medicine.

Today, because of patients like Victoria, that once-experimental therapy is now an FDA-approved treatment that is changing lives around the country.

Why This Story Hits Home

Victoria's journey resonates deeply with me because our stories share something important.

In 2017, after being diagnosed with metastatic triple-negative breast cancer, I enrolled in an immunotherapy clinical trial at NYU. At that time, there were no guarantees. Like so many patients who volunteer for research, I didn't know whether the treatment would help me, help future patients, or neither.

Nearly a decade later, I remain alive because of that decision.

When I looked at Victoria during her presentation, I didn't just see a keynote speaker.

I saw another patient who chose hope over fear.

I saw someone who understood that participating in research isn't just about ourselves. It's about the people who come after us.

Why This Matters for the Black Community

Sickle cell disease primarily affects people of African ancestry, yet for decades it received far less research attention and investment than many other diseases. Families have endured generations of painful crises, repeated hospitalizations, organ damage, and shortened life expectancy.

Now, we're witnessing something many thought impossible.

A treatment designed to correct the underlying genetic cause of the disease.

For Black communities, this is more than a scientific achievement.

It represents hope.

It represents equity.

It demonstrates what becomes possible when researchers invest in diseases that disproportionately affect historically underserved populations.

The Power of Clinical Trials

As a patient navigator, one of the most common questions I hear is:

"Why should I consider a clinical trial?"

Daniel's story is the answer.

Victoria's story is the answer.

Clinical trials are how today's experiments become tomorrow's standard of care.

Without patients willing to participate years ago, Daniel may never have had access to the treatment that changed his life.

Every approved cancer drug...

Every new immunotherapy...

Every targeted treatment...

Every gene-editing breakthrough...

Started with patients who volunteered to move science forward.

Looking Ahead

Medical breakthroughs don't happen overnight.

They happen because researchers dedicate years to discovery.

They happen because physicians refuse to stop asking questions.

And most importantly, they happen because patients are willing to participate in research that may help not only themselves, but generations they will never meet.

As I stood beside Victoria Gray, I couldn't help but smile.

Not because we share the same diagnosis.

But because we share something equally powerful.

We are both living proof that behind every medical breakthrough is a patient whose courage helped make it possible.

And that may be the most important lesson of all.

Hugs.

Karen